Cancer Currents: An NCI Cancer Research Blog
A blog featuring news and research updates from the National Cancer Institute. Learn more about Cancer Currents.
-
NCI’s Office of Cancer Survivorship: Celebrating 20 Years, Planning for Continued ProgressDr. Julia Rowland, director of NCI’s Office of Cancer Survivorship, on the office’s 20th anniversary and efforts to ensure continued progress in survivorship research and improve survivors’ lives.
-
More Immunotherapy Options Approved for Lung CancerThe FDA has approved atezolizumab and expanded the approval of pembrolizumab for some patients with non-small cell lung cancer.
-
Connected Health: An Important Tool for Making Progress against Cancer
A new report from the President’s Cancer Panel outlines how connective technologies can promote cancer prevention, enhance patients’ treatment experience, and accelerate progress in cancer research.
-
CDC Updates Recommendations on HPV VaccineUpdated CDC recommendations advise those younger than age 15 need only two doses of the HPV vaccine instead of three.
-
Symposium Brings Rising Global Cancer Burden into FocusAn NCI Cancer Currents blog post about the NCI Global Cancer Research Symposium, which examined ways of increasing research collaboration, particularly in cancer prevention and screening, to reduce the cancer burden.
-
Olaratumab Approved to Treat Advanced Soft Tissue SarcomaThe Food and Drug Administration (FDA) has granted accelerated approval to olaratumab (Lartruvo®) for the treatment of some patients with soft tissue sarcoma.
-
Scientists Identify Potential Marker of Resistance to PARP InhibitorsFindings from a new study from NCI researchers could help predict whether a tumor will respond to a new class of promising cancer drugs, and identifies a potential way to overcome that resistance.
-
‘Unexpected’ Vulnerability Creates Treatment Opportunity in Aggressive Type of Lung CancerA new study has identified a potentially critical vulnerability in lung cancers that have mutations in the KRAS gene, and showed that a drug already under study may be able to exploit it.
-
DINO RNA Molecule Triggers Anticancer Response in Damaged CellsStudies in cells and mice found that, in cells with damaged DNA, a noncoding RNA called DINO stabilizes the p53 protein and guides the cells into cell death, preventing tumor development.
-
Modified Immunotherapy Approach Shows Promise for LeukemiaResearchers have developed an immunotherapy approach that uses immune cells whose natural cancer killing abilities have been enhanced in the lab. In a small clinical trial, the treatment led to remissions in about half of patients with acute myeloid leukemia.
-
Metabolomics Study Reveals another Energy Source for Cancer CellsResearchers have found that cancer cells can use the compound lactate to fuel biochemical reactions and to generate other compounds they need for growth and survival.
-
New on NCI Websites for October 2016An NCI Cancer Currents blog post that provides updates on new NCI websites and other online content of interest to the cancer community.
-
Educating Patients about Genetic Test Results: An Interview with Carol Weil about the COMET StudyThe recently launched COMET study will examine whether educating patients with cancer about genetic testing will increase their knowledge and reduce their stress levels after receiving genomic testing results.
-
Avelumab Induces Sustained Tumor Responses in Some Patients with Rare Skin CancerIn a phase II clinical trial, some patients with metastatic Merkel cell carcinoma whose cancer has progressed despite treatment with chemotherapy had durable tumor responses to the immunotherapy drug avelumab.
-
Study Confirms Benefits of Early Palliative Care for Advanced CancerA randomized clinical trial has found that patients who received palliative care along with standard treatment for advanced cancer reported having a better quality of life and mood than patients who did not receive early palliative care.
-
TARGET Initiative Fueling Progress against Childhood LeukemiaResearch from TARGET, an NCI-funded program supporting genomic analyses of childhood cancers, has led to the launch of several clinical trials of targeted therapies to treat children with acute lymphoblastic leukemia.
-
Studies Highlight Potential of Targeting HIF-2 in Kidney CancerTwo new studies suggest that a new class of drugs can effectively target a molecular driver of the most common type of kidney cancer.
-
Many Cancer Caregivers Report Feeling Unprepared for Caregiving ChallengesMany family members who care for loved ones with cancer do not feel adequately prepared for the caregiving tasks they assume and need help to make informed decisions about end-of-life care, according to a new study.
-
Chromosomal Instability Score May Predict Response to Cancer TreatmentA new study suggests that a chromosomal instability score may help guide treatment choices for patients with cancer.
-
Forging Collaborations to Spur Global Progress against CancerNCI and NIH announce efforts to establish international collaborations that can accelerate progress in reducing the global cancer burden.